Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives $7.14 Consensus Price Target from Analysts

Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) have received a consensus rating of “Hold” from the nine brokerages that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and three have assigned a buy rating to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $7.1429.

Several brokerages have weighed in on NMRA. Mizuho raised their price objective on shares of Neumora Therapeutics from $4.00 to $5.00 and gave the company an “outperform” rating in a research note on Wednesday, July 16th. Needham & Company LLC reiterated a “buy” rating and issued a $5.00 price objective on shares of Neumora Therapeutics in a report on Tuesday, May 13th.

Neumora Therapeutics Stock Performance

NMRA opened at $1.63 on Friday. Neumora Therapeutics has a 1 year low of $0.61 and a 1 year high of $17.19. The company has a current ratio of 10.54, a quick ratio of 10.54 and a debt-to-equity ratio of 0.11. The stock’s 50 day simple moving average is $1.31 and its 200-day simple moving average is $1.16. The stock has a market cap of $263.98 million, a PE ratio of -1.04 and a beta of 2.91.

Neumora Therapeutics (NASDAQ:NMRA) last posted its earnings results on Wednesday, August 6th. The company reported ($0.33) earnings per share for the quarter, topping the consensus estimate of ($0.38) by $0.05. Sell-side analysts forecast that Neumora Therapeutics will post -1.61 EPS for the current year.

Hedge Funds Weigh In On Neumora Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in NMRA. Invesco Ltd. boosted its stake in shares of Neumora Therapeutics by 6.8% in the second quarter. Invesco Ltd. now owns 132,038 shares of the company’s stock valued at $97,000 after buying an additional 8,383 shares during the period. CWM LLC lifted its position in shares of Neumora Therapeutics by 41.8% during the 2nd quarter. CWM LLC now owns 35,750 shares of the company’s stock valued at $26,000 after acquiring an additional 10,537 shares during the period. PEAK6 LLC acquired a new stake in shares of Neumora Therapeutics during the 4th quarter worth $117,000. Wells Fargo & Company MN grew its holdings in shares of Neumora Therapeutics by 23.0% during the 4th quarter. Wells Fargo & Company MN now owns 70,653 shares of the company’s stock worth $749,000 after purchasing an additional 13,196 shares in the last quarter. Finally, Numerai GP LLC increased its position in shares of Neumora Therapeutics by 46.7% in the fourth quarter. Numerai GP LLC now owns 51,696 shares of the company’s stock worth $548,000 after purchasing an additional 16,457 shares during the period. Institutional investors and hedge funds own 47.65% of the company’s stock.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.